350797-52-3

Basic information

• Product Name: 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-1H-indole-5-carboxaldehyde
• Synonyms: 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-1H-indole-5-carboxaldehyde;1H-Indole-5-carboxaldehyde, 1-[3-(benzoyloxy)propyl]-2,3-dihydro-;3-(5-ForMylindolin-1-yl)propyl benzoate
• CAS NO: 350797-52-3
• Molecular Formula: C₁₉H₁₉NO₃
• Molecular Weight: 309
• Mol File: 350797-52-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 504.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.200
• Storage Temp.: 2-8°C
• PKA: 2.75±0.20(Predicted)
• CAS DataBase Reference: 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-1H-indole-5-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-1H-indole-5-carboxaldehyde(350797-52-3)
• EPA Substance Registry System: 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-1H-indole-5-carboxaldehyde(350797-52-3)

Safety Data

• Hazardous Substances Data: 350797-52-3(Hazardous Substances Data)

Usage

General Description

1-[3-(benzoyloxy)propyl]-2,3-dihydro-1H-Indole-5-carboxaldehyde, also known as BPI, is a chemical compound that belongs to the class of indole derivatives. It is a yellow solid that is used in organic synthesis and pharmaceutical research. BPI has potential applications in the development of new drugs and pharmaceutical products due to its diverse pharmacological properties. It is commonly used as a starting material for the synthesis of various biologically active molecules. BPI has also been studied for its potential role in the treatment of various medical conditions, such as cancer and neurological disorders. Overall, BPI is an important chemical compound with potential therapeutic applications in the pharmaceutical industry.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 65-85-0 benzoic acid 
• 496-15-1 1-indoline 
• 350797-51-2 1-(3-benzoyloxypropyl)-2,3-dihydroindole hydrochloride 

Downstream Products

• 350797-53-4 1-(3-benzoyloxypropyl)-5-(2-nitro-1-propenyl)-2,3-dihydroindole 
• 160970-54-7 silodosin 
• 239463-72-0 5-[(2R)-2-aminopropyl]-2,3-dihydro-1-[3-(benzoyloxy)propyl]-1H-indole-7-carbonitrile 
• 885340-11-4 2,3-dihydro-1-[3-(benzoyloxy)propyl]-5-[(2R)-2-[[2-[(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile 
• 885340-13-6 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carbonitrile 
• 350797-54-5 1-(3-benzoyloxypropyl)-5-(2-nitropropyl)-2,3-dihydroindole 
• 350797-55-6 1-(3-benzoyloxypropyl)-7-formyl-5-(2-nitropropyl)-2,3-dihydroindole 
• 350797-56-7 1-(3-benzoyloxypropyl)-7-cyano-5-(2-nitropropyl)-2,3-dihydroindole 
• 1338365-54-0 5-(2-aminopropyl)-1-[3-(benzoyloxy)propyl]-2,3-dihydro-7-cyano-1H-indole 

Relevant articles and documents

Preparation method of indoline derivative for synthesizing silodosin

The invention provides a preparation method of an indoline derivative for synthesizing silodosin. Indoline is taken as a starting raw material and reacts with benzoic acid and 1-chloro-3-bromopropane to prepare a compound (1); a reaction is carried out in a Vilsmeier agent, and a formyl group in introduced to the 5th position to prepare a compound (2); the compound (2) and nitroethane undergoes an asymmetric Henry reaction in the catalysis of quinidine-copper acetate to prepare a compound (3); the compound (3) is subjected to acetylation through acetic anhydride to prepare a compound (4); a cyano group is introduced to the 7th position to prepare a compound (6); and two functional groups are reduced through palladium-on-carbon hydrogenation in one step to obtain a high-chiral-purity target compound: (R)-1-[1-(3-benzoyloxypropyl)-5-(2-aminopropyl)-7-cyano]indoline. In the early stage of the method, cheap quinidine is used to perform an asymmetric Henry reaction for introduction of chiral centers, thereby avoiding resolution in the latter stage. The method is reasonable in design, simple to operate, effectively improved in yield and reduced in cost, and therefore is suitable for massive production.

METHOD FOR PREPARING SILODOSIN

The present invention relates to a process for preparing silodosin with high optical purity up to 99.9% enantiomeric excess (e.e.) or above. The process makes use of a method step, in which the enantiomers contained in a racemic mixture of a compound represented by the general formula V: wherein * denotes the asymmetric center, R1 is a protecting group, and R2 is cyano or carbamoyl, are separated.